ArticleAlimentary pharmacology & therapeutics2021
Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study.
Article in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Circulating microRNA as Biomarkers for Gestational Diabetes Mellitus-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Transcriptomic Profiling of MicroRNA and Non-Coding RNA from Whole Blood of African Americans with MASLD.International journal of molecular sciences · 2026Article
- MiR-18a-5p Attenuates Oxidative Stress and Inhibits Lipid Accumulation in Alcoholic Fatty Liver by Activating the CYP1A1-PPAR Axis.Immunity, inflammation and disease · 2026Article
- Plasma Extracellular MicroRNAs Associated With Cardiovascular Disease Risk Factors in Middle-Aged and Older Adults.Journal of the American Heart Association · 2024Article
- Plasma circulating microRNAs associated with blood-based immune markers: a population-based study.Clinical and experimental immunology · 2024Article
- Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.International journal of clinical practice · 2024Article
- Smoking-related dysregulation of plasma circulating microRNAs: the Rotterdam study.Human genomics · 2023Article
- Plasma MicroRNA Signature of Alcohol Consumption: The Rotterdam Study.The Journal of nutrition · 2023Article
- Plasma circulating microRNAs associated with obesity, body fat distribution, and fat mass: the Rotterdam Study.International journal of obesity (2005) · 2022Article
- Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat.International journal of molecular sciences · 2022Article
- Multiomics analysis of the impact of polychlorinated biphenyls on environmental liver disease in a mouse model.Environmental toxicology and pharmacology · 2022Article
- Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.JHEP reports : innovation in hepatology · 2022Article
- Association of circulating miRNAS in patients with Alstrőm and Bardet-Biedl syndromes with clinical course parameters.Frontiers in endocrinology · 2022Article
- Circulating MicroRNAs, Polychlorinated Biphenyls, and Environmental Liver Disease in the Anniston Community Health Survey.Environmental health perspectives · 2022Article
- Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients.International journal of molecular sciences · 2021Article
- Circulatory MicroRNAs in Plasma and Atrial Fibrillation in the General Population: The Rotterdam Study.Genes · 2021Article
- MicroRNA‑378d inhibitsMolecular medicine reports · 2021Article
- Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study.Alimentary pharmacology & therapeutics · 2021Article
- Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases.Gastroenterology and hepatology from bed to bench · 2021Review
- The Role of miRNAs and Epigenetic Factors in Non-Alcoholic Fatty Liver Disease - a Systematic Review.Current health sciences journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFatty liver disease (FLD) is the most common cause of liver dysfunction in developed countries. There is great interest in developing clinically valid and minimally invasive biomarkers to enhance early diagnosis of FLD.
aimTo investigate the potential of circulatory microRNAs (miRNAs) as biomarkers of FLD at the population level.
methodsPlasma levels of 2083 miRNAs were measured by RNA sequencing in 1999 participants from the prospective population-based Rotterdam Study cohort. The Hounsfield Unit (HU) attenuation of liver was measured using non-enhanced computed tomography (CT) scan. Logistic and linear regression models adjusting for potential confounders were used to examine the association of circulatory miRNAs with liver enzymes (n = 1991) and CT-based FLD (n = 954). Moreover, the association of miRNAs with hepatic steatosis and liver fibrosis was assessed longitudinally in individuals who underwent abdominal ultrasound (n = 1211) and transient elastography (n = 777) after a median follow-up of >6 years.
resultsCross-sectional analysis showed 61 miRNAs significantly associated with serum gamma-glutamyl transferase and/or alkaline phosphatase levels (Bonferroni-corrected P < 8.46 × 10
conclusionsPlasma levels of several miRNAs can be used as biomarkers of FLD, laying the groundwork for future clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.